Citations

Clear

439 citation(s) found for "Stone, M".

Inside Front Cover: On the Discorhabdins Leading to the Aleutianamine Ring System: A One‐Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology (Angew. Chem
Potluri, Abhay , Bland, Alison M. , Flipse, Samuel M., Hanna, George S., Wagner, Ryan T. , Ho, Thai H., Hoff, Gerald R., Stone, R.N., Tius, Marcus A. , Tantillo, Dean J., Hamann, Mark T., Dickinson, Cody F. , Hanna, George S. , Robertson, Keith D. , Sprague, Daniel J. , Tantillo, Dean J , Hamann, Mark T

Mayo Clinic

Angewandte Chemie | March 19, 2026 | Volume: 138 | Issue: 17 | Pages: No page available

10.1002/ange.2026-m1603034200 Get It

Inside Front Cover: On the Discorhabdins Leading to the Aleutianamine Ring System: A One‐Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology (Angew. Chem
Potluri, Abhay , Bland, Alison M. , Flipse, Samuel M., Hanna, George S., Wagner, Ryan T. , Ho, Thai H., Hoff, Gerald R., Stone, R.N., Tius, Marcus A. , Tantillo, Dean J., Hamann, Mark T., Dickinson, Cody F. , Hanna, George S. , Robertson, Keith D. , Sprague, Daniel J. , Tantillo, Dean J , Hamann, Mark T

Mayo Clinic

Angewandte Chemie International Edition | March 19, 2026 | Volume: 65 | Issue: 17 | Pages: No page available

10.1002/anie.2026-m1603034200 Get It

On the Discorhabdins Leading to the Aleutianamine Ring System: A One‐Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology
Dickinson, Cody F. , Potluri, Abhay , Bland, Alison M. , Flipse, Samuel M., Hanna, George S., Wagner, Ryan T. , Ho, Thai H., Hoff, Gerald R., Stone, R. S., Tius, Marcus A. , Tantillo, Dean J., Hamann, Mark T., Dickinson, Cody F , Hanna, George S. , Robertson, Keith D. , Sprague, Daniel J. , Stone, Robert P., Tantillo, Dean J , Hamann, Mark T

Mayo Clinic

Angewandte Chemie | February 16, 2026 | Volume: 138 | Issue: 17 | Pages: No page available

10.1002/ange.7864883 Get It

ABSTRACT We disclose an efficient transformation of the relatively common pyrroloiminoquinone discorhabdin alkaloids from Alaskan Latrunculia spp. to the complex ring system of aleutianamine by an acid catalyzed process that mimics the proposed endogenous genesis from 3‐dihydrodienyl discorhabdin precursors. The azepine ring system is formed by a concerted 1,2‐alkyl shift of a proposed thiocarbenium‐iminium dication and this mechanism is supported by extensive density functional theory (DFT) analysis. Additional in vitro biological data further supports the aleutianamines as novel and highly potent inhibitors of multidrug resistant cancer lines exemplified further with cytotoxicity toward chemotherapy resistant chromophobe renal cell carcinoma (IC 50 = 130 nM). This report provides a key transformation that allows the incorporation of either synthetic or biosynthetic starting materials leading to the generation of the aleutianamine complex ring system in just a single step from the discorhabdin ring system.
On the Discorhabdins Leading to the Aleutianamine Ring System: A One‐Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology
Potluri, Abhay , Bland, Alison M. , Flipse, Samuel M., Hanna, George S., Wagner, Ryan T. , Ho, Thai H., Sprague, Daniel J. , Hoff, Gerald R., Stone, R. S., Tius, Marcus A. , Tantillo, Dean J., Hamann, Mark T., Dickinson, Cody F , Tantillo, Dean J , Hamann, Mark T , Dickinson, Cody F. , Hanna, George S. , Robertson, Keith D. , Stone, Robert P.

Mayo Clinic

Angewandte Chemie International Edition | February 16, 2026 | Volume: 65 | Issue: 17 | Pages: No page available

10.1002/anie.7864883 | PMID 41693117 Get It

ABSTRACT We disclose an efficient transformation of the relatively common pyrroloiminoquinone discorhabdin alkaloids from Alaskan Latrunculia spp. to the complex ring system of aleutianamine by an acid catalyzed process that mimics the proposed endogenous genesis from 3‐dihydrodienyl discorhabdin precursors. The azepine ring system is formed by a concerted 1,2‐alkyl shift of a proposed thiocarbenium‐iminium dication and this mechanism is supported by extensive density functional theory (DFT) analysis. Additional in vitro biological data further supports the aleutianamines as novel and highly potent inhibitors of multidrug resistant cancer lines exemplified further with cytotoxicity toward chemotherapy resistant chromophobe renal cell carcinoma (IC 50 = 130 nM). This report provides a key transformation that allows the incorporation of either synthetic or biosynthetic starting materials leading to the generation of the aleutianamine complex ring system in just a single step from the discorhabdin ring system.
Residual Stone Volume Predicts Health Care Consumption and Stone Events: Analysis of Two-Year Results of the ASPIRE Study
Matlaga, Brian R., Johnson, Brett, Page, Jay, Wolf, J. Stuart, Preminger, Glenn M. , Jones, Loren, Sobol, Ilya , Stern, Karen , Lipkin, Michael, Cuellar, David, Cobb, Kaitlan, Barsky, Robert, Medairos, Robert, Marguet, Charles G., Nimmagadda, Naren , Levin, Michael, Chi, Thomas, Stern, Karen L , Mueller, Thomas J. , Wolf, Jeanette, Jones, Loren, Lipkin, Michael E. , Cuellar, David, Barsky, Robert I, White, Mark, Chi, Thomas

Mayo Clinic

Journal of Endourology | February 12, 2026 | Volume: 40 | Issue: 3 | Pages: 328-334

10.1177/08927790261420565 | PMID 41674087 Get It

Purpose: The ASPiration to Improve Renal Calculi Removal Effectiveness study showed steerable ureteroscopic renal evacuation (SURE) with CVAC that significantly reduced residual stone volume at 30 days vs standard ureteroscopy (URS). This report presents 2-year health care consumption and stone events (SE) and their link to residual stone volume and other variables ( n = 101 at primary end point; n = 93 at 2 years). Materials and Methods: Logistic regression identified predictors of health care consumption events (HCEs), that is, emergency department visits, hospitalization, surgical retreatment, and SE across the study population. Incidence was compared between the treatment groups with Kaplan–Meier survival analysis. Results: At 2 years, residual stone volume was significantly associated with both HCEs and SE. For every 100 mm 3 increase in residual stone volume, the HCE risk increased by 50% to 54%, and the SE risk increased by 70%. Stone-free rate, the number of residual fragments (RFs), and RF total stone burden (based on diameter) were not predictors. Significantly fewer HCEs occurred in the SURE group (3 vs 20 events, p = 0.0004). Survival analysis confirmed this (4.3% vs 20%, log-rank p = 0.02), with a 73% risk reduction (hazard ratio 0.27, 95% Cl 0.09–0.80, p = 0.02). Fewer SE occurred in the SURE group, although not statistically significant. These subjects also had longer event-free survival. Conclusion: High-quality volumetric analysis supports evaluation of stone removal therapies, as residual stone volume predicts HCEs and SE. SURE significantly reduces the downstream incidence and risk of HCEs compared with standard URS.
Serous Ovarian Cancer Following Opportunistic Bilateral Salpingectomy
Sowamber, Ramlogan , Mei, Alice J. , Kaur, Paramdeep, McLeod, Julianne, McKay, Emily , Lukey, Alex, Bakkum-Gamez, Jamie, Buza, Natalia, Cohen, Paul A., Farrell, Rhonda, Garcia, Christine, Gilks, Blake, Goode, Ellen, Howitt, Brooke, Hui, Pei, Köbel, Martin , Kushi, Lawrence, Kwon, Janice, Long-Roche, Kara C., Malpica, Anais, McAlpine, Jessica N., Miller, Dianne , Oliva, Esther, Paliga, Aleksandra, Parra-Herran, Carlos, Pearce, Celeste Leigh , Piek, Jurgen Martinus, Qiu, Haiyan, Rabban, Joseph T. , Rome, Robert, Steenbeek, Miranda, Stone, R., Talhouk, Aline , Tischer, Kristin M., Huntsman, David G., Howitt, Brooke E. , Cohen, Paul A. , Piek, Jurgen M.J. , Tischer, Kristin M. , Köbel, Martin , Cohen, Paul , Kaur, Paramdeep , Bakkum‐Gamez, Jamie N. , Buza, Natália , Devins, Kyle M. , Farrell, Rhonda , Garcia, Christine , Gilks, C. Blake , Goode, Ellen L. , Hodgson, Anjelica , Hui, Pei, Huvila, Jutta , Karnezis, Anthony N. , Keyhanian, Kianoosh , Kinloch, Mary A. , Kommoss, Felix , Kushi, Lawrence H. , Kwon, Janice S. , Malpica, Anais, McAlpine, Jessica N. , Oliva, Esther , Palicelli, Andrea , Parra‐Herran, Carlos , Perera, Sharnel , Steenbeek, Miranda, Tischer, Kristin M. , Trabert, Britton , Webb, Penelope M. , Zalcberg, John , Huntsman, David G. , Hanley, Gillian E.

Mayo Clinic

JAMA Network Open | February 2, 2026 | Volume: 9 | Issue: 2 | Pages: e2557267

10.1001/jamanetworkopen.2025.57267 | PMID 41627818 Get It

This cohort study evaluates the reduction in risk of high-grade serous carcinoma among women undergoing opportunistic bilateral salpingectomy in Canada.
Challenges in Structuring SARS-CoV-2 Emergency Use Authorization Diagnostics Data: Leveraging Findable, Accessible, Interoperable, and Reusable Principles for the Next Era of Diagnostic Data Transparency
Phillips, Alexander J., Glieberman, Aaron L, Gallegos, Christina, Morrison, Anthony , Reed, Michael R., Baron, Veronique T, Dinakar, Karthik , Borchers, Anna, Stone, Webb, Ishack, Stephanie , Rajesh, Singh, Weinstock, Samantha Bates, Luu, Hung S. , Lin, Yu , Merrick, Riki, Luu, Hung S , Phillips, Alexander J., Glieberman, Aaron L. , Gallegos, Christina, Reed, Michael R., Baron, Veronique T. , Borchers, Anna , Okda, Faten A. , Stone, Webb, Don, Sujeewa Sampath Lellupitiyage, Creager, Richard S.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 21, 2026 | Volume: 150 | Issue: 5 | Pages: 381-390

10.5858/arpa.2025-0144-oa | PMID 41386638 Get It

Context.— The US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for SARS-CoV-2 assays encompassed both in vitro diagnostic and laboratory-developed tests. Related testing data and documents from EUAs were published on the FDA website as PDF files, constituting a rich data resource. Objective.— To highlight the value of structured descriptive and validation data and provide recommendations on improving the quality, accessibility, and shareability of the FDA’s digital resources. Design.— SARS-CoV-2 diagnostics EUAs and related files were acquired from the FDA, and data were extracted through an iterative manual or automated process with quality assurance in accordance with a set of data entry definitions to generate a data product (ie, data analysis and presentation of data into tables, graphs, and reports, optionally including different data sets) that could be disseminated. Results.— Four challenges limited the usability of FDA EUA data, including (1) distinguishing EUA tests owing to similar names or inconsistent naming conventions; (2) document location and tracking owing to inconsistent EUA document identifiers, resource locators, and versioning; (3) data location and retrieval owing to heterogeneous structure and data formatting within EUA documentation; and (4) maintenance of existing data owing to lack of clear and traceable communication around EUA amendments. Conclusions.— Converging efforts from disparate groups to extract and synthesize FDA test data reveal an unaddressed need for better organization and communication. Existing FDA data reporting systems must be improved and adapted for the demands of the connected data science era.
Exercise recommendations for older adults living with and beyond cancer: A consensus statement by the Advancing Capacity to Integrate Exercise Into the Care of Older Cancer Survivors expert panel
Winters‐Stone, Kerri M. , Meyers, G., Cheville, Andrea , Garcia, José M. , Mohile, Supriya G. , Mustian, Karen, Neil‐Sztramko, Sarah, Schwartz, Anna L. , Sitemba, Jessica, Smith, Robert, Campbell, K., Mustian, Karen M. , Neil‐Sztramko, Sarah , Cheville, Andrea L , McNeely, Margaret L , Neil-Sztramko, Sarah , Schmitz, Kathryn H , Campbell, Kristin L , Winters-Stone, Kerri M , Garcia, Jose M , Eckstrom, Elizabeth , Rogers, Laura Q. , Schmitz, Kathryn H.

Mayo Clinic

Cancer | January 7, 2026 | Volume: 132 | Issue: 2 | Pages: No page available

10.1002/cncr.70252 | PMID 41499155 Get It

Abstract Background The number of cancer survivors aged older than 65 years is rising rapidly. Current evidence‐based exercise guidelines lack specific guidance for older cancer survivors as a result of insufficient evidence. An expert panel was convened to develop consensus‐based recommendations for exercise in older cancer survivors. Methods The development of recommendations was guided by the Grading of Recommendations Assessment, Development, and Evaluation Evidence‐to‐Decision framework for good practice statements. The panel drew from the available literature, a Delphi survey of exercise and health professionals, other exercise guidelines, clinical and research expertise, and interest‐holder input provided by a community advisory board of older cancer survivors and caregivers ( n = 11). Recommendations had to be deemed accessible (i.e., no added barriers) to older cancer survivors and feasible to implement. The panel voted on the strength of the recommendation for or against each statement, with consensus set at 85% agreement. Results Consensus was reached on 11 recommendations covering the following areas: medical evaluation/clearance for exercise, pre‐exercise assessment, exercise prescription, exercise tolerance and safety, exercise delivery, and behavioral support. The recommendations aimed to promote engagement in and uptake of appropriately prescribed exercise programming by older cancer survivors, while keeping barriers and risks as low as possible. Conclusions Older cancer survivors can benefit from appropriately prescribed exercise, which should be an essential component of their cancer care. Exercise and health professionals need to consider the unique needs of older cancer survivors to ensure that exercise is safe and effective for this population, while also reducing barriers to reach as many people as possible.
Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies
Beck, Roy W. , Hirsch, Irl B., Raghinaru, Dan, Lum, John W. , Pinsker, Jordan E. , Kudva, Yogish C. , Group*, 2IQP Study, Desjardins, Donna, Kurek, Corey, Kaur, Ravinder Jeet , Livingood, Daine, Rizvi, Shafaq , Graham, Timothy E., Terry, Adrienne, Luker, Ryan, Mellenthin, Melanie, Rezac, Stephanie, Liljenquist, David R., Rogers, Justin, Williams, Jonathan, Christensen, Rochelle, Lee, In‐Kyoung, Malone, Joann, Spanakis, Elias K. , Singh, Lakshmi G., Churchill, Jade, Comen, Kathleen, Scott, William H., Davis, Georgia M. , Arroyo, Lizda Guerrero, Oladejo, Omolade , Usman, Sabeena, Ahmann, Andrew , Schmid, Caleb, Dean, Ariel, Branigan, Deborah , Caswell, Brittany, Heyerman, Tess, Tessman, Brian, Vanderheide, Jnh, Dennis, Brittany , Hendricks, Lisa, Reyes-Rodriguez, Clemente, Wolf, Valerie, Coyne, Kasey, Kravarusic, Jelena, Fronczyk, Evelyn, Herrmann, Stefanie, Penn, Samsam C., Blevins, Thomas , Casaubon, Luis, Espinosa, Valerie, Pandit, Keta, Perez, Jennifer, Stewart, Ana, Assir, Courtney, Fields, Cory, Kruger, Davida , Estrada, Kathleen, Jones, J. Kimberly, Mukhashen, Shereen, Corker, Natalie, Hunter, Heather, Layton, Paula, Brown, Sue A. , Afreen, Samina , Dhillon, Jasmeen, Emory, Emma, Fulkerson, David, Fuller, Morgan, Holmes, Viola, Kollar, Laura, Toole, Elyse, Levister, Camilla, O’Malley, Grenye , Ipek, Aslihan, Alabi, Denise, Ellis, Emily, Hassan, Shaziah, Ogyaadu, Selassie, Tamarez, Denisa, Weinstock, Ruth S. , Stone, Sheri , Bzdick, Suzan, Agostini, Lynn, Bulger, Jane , Wolpert, Howard , Atakov-Castillo, Astrid , Sullivan, Asya, Aia, Corinne, Brouillard, Elizabeth, Driscoll, Marsha, Lapier, Heather, Payra, Sherryl, Vancer, Louise, Averkiou, Xenia, Baran, Jesica, Holod, Rosanna, Litvicov, Patrisia, Mandava, Patali, Swinton, Sydney, Khakpour, Dori , Broyles, Frances E. , Marks, Sheryl, Mitchell, Tina, Hairston, Babette, Costello, Reilly, Curtis, Stella, Kamimoto, Jorge Jo, Peleckis, Amy J. , Sultan, Rahaf , Dalton-Bakes, Cornelia, Bourne, Patricia, Haidar, Ahmad, Pasqua, Melissa, Tardio, Vanessa , Moore, Adelyn, Kemp, Gabrielle, Raskin, Philip, Jordan, L.F., Shao, Baomei, DoNguyen, Trang, Meeks, Tram, Phan, Michael , Lesniak, Amanda, Becerra, Mario, Bellini, Natalie J. , Denallo, Erica, Lewis, Claudia , Tribout, Jerry, Tribout, Megan, DiFrancesco, Kathryn, Phillips, Kylie, Raghinaru, Dan, Campos, Tiffany, Morrell, Beth, Oduah, Vanessa, Cardenas-Villamil, Gabriela, Morales, Amanda, Murphy, Carlos, Strayer, Heidi, Spanbauer, Charles , Kollman, Craig, Sasson-Katchalski, Ravid, Piquette, Nicole, Wheatcroft, Alex, WHITE, KIRSTIN N., Carmelo, KC, Janicek, Robert, Gabrielson, Deanna, Mercado, Kevin, Beck, Roy W , Group*, 2IQP Study, Smith, Joshua W. , Christensen, Rochelle, Malone, Joann, Pasquel, Francisco J. , Tajrishi, Farbod Zahedi , Arroyo, Lizda Guerrero, Dean, Ariel, Howard, Matthew, Vander-Heide, Jesse, Ahn, David , Aleppo, Grazia , Fields, Cory, Layton, Paula, Oliveri, Mary Clancy , Levy, Carol J. , Agostini, Lynn, Steenkamp, Devin W , Spaic, Tamara , Liu, Selina , Marks, Sheryl, Mitchell, Tina, Costello, Reilly, Curtis, Stella, Rickels, Michael R. , Bourne, Patricia, Tsoukas, Michael A. , Pasqua, Melissa-Rosina , Moore, Adelyn, Kemp, Gabrielle, Meeks, Tram, Phan, Michael, Hatipoğlu, Betül , Lesniak, Amanda, Howard, Quiana , DiFrancesco, Kathryn, Raghinaru, Dan, Morrell, Beth, Morales, Amanda, Kanapka, Lauren , Le, Van

Mayo Clinic

Diabetes Care | December 5, 2025 | Volume: 49 | Issue: 2 | Pages: e18-e20

10.2337/dc25-2059 | PMID 41348329 Get It